Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (3246)	11/12/2000 6:33:35 PM
From: DanZ	Read Replies (1) \| Respond to of 5582

According to Quigley's press release last week, The Federal Trade Commission (FTC) has sustained The Quigley Corporation's advertising claims that Cold-Eeze can reduce the duration and severity of the symptoms of the common cold. The same applies to Gum Tech's claim that Zicam reduces the duration of the symptoms of the common cold, except that Gum Tech can claim 75% reduction for Zicam while Quigley can only claim 42% reduction for Cold Eeze. I don't have to provide any evidence to prove anything to you. Gum Tech conducted two independent double-blind placebo-controlled clinical studies that prove Zicam works. The results of the study have been published in a reputable peer reviewed medical journal and your ranting and raving won't change anything. Bye!